Skip to content
OpenCapital
Get started

BioMarin Pharmaceuticals BMRN Available For Sale Securities Debt Securities Current

Available For Sale Securities Debt Securities Current at other companies

BridgeBio Pharma logo
BridgeBio PharmaBBIO
——
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
——
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
——
Biogen logo
BiogenBIIB
——
Globus Medical logo
Globus MedicalGMED
——
Cytokinetics logo
CytokineticsCYTK
——

Other financials

Income statement

See full
Revenue$766.2M+2.8%
Gross profit$571.2M-3.8%
Operating income$129.6M-42.1%
Net income$105.5M-43.2%
EPS (diluted)$0.54-43.2%

Balance sheet

See full
Cash & equivalents$3.1B+193%
Total debt$1.4B+138%
Total equity$6.2B+7.2%
Total assets$8.6B+20.2%

Cash flow

See full
Operating cash flow$220.7M+26.5%
CapEx$20.9M+24.8%
Free cash flow$199.7M+26.7%

Valuation

See full
Market cap$10.57B-19.4%
Enterprise value$8.93B-29.3%
P/E21.1×-22.7×
P/S3.3×-1.2×

Profitability

See full
Gross margin76.5%-2.9pp
Operating margin19.9%+7.2pp
Net margin16.8%+5.1pp
FCF margin23.7%+2.5pp

Returns & leverage

See full
Return on equity9.1%+2.8pp
Debt / equity0.2×+0.1×
Current ratio5.8×+0.3×

Where this comes from

Reported directly by BioMarin Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.

The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioMarin Pharmaceuticals's available for sale securities debt securities current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioMarin Pharmaceuticals's available for sale securities debt securities current?
BioMarin Pharmaceuticals (BMRN) reported available for sale securities debt securities current of $0 in Q1 2026.
How has BioMarin Pharmaceuticals's available for sale securities debt securities current changed year-over-year?
BioMarin Pharmaceuticals's available for sale securities debt securities current decreased by 100.0% year-over-year, from $223.53M to $0.
What is the long-term trend for BioMarin Pharmaceuticals's available for sale securities debt securities current?
Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's available for sale securities debt securities current has grown at a -9.8% compound annual growth rate (CAGR), from $416.23M to $248.93M.